Dowden Nathan J 4

What Happened
Nathan J. Dowden, President & COO of Entrada Therapeutics (TRDA), received equity awards and had shares sold to cover tax withholding. The filing shows two grants totaling 139,000 award units (55,800 and 83,200) reported as acquisitions at $0.00 (RSUs/derivative). To satisfy tax obligations, 7,223 shares were sold on 2026-03-02 for a weighted average price of $11.66 (≈ $84,205) and 14,038 shares were sold on 2026-03-03 for a weighted average price of $11.76 (≈ $165,036). Total proceeds from those automatic sales were about $249,241.

Key Details

• Transaction types: A = Award/Grant (RSUs/derivative); F = payment of exercise price or tax liability (sell-to-cover).
• Grants: 55,800 RSUs (reported A) and 83,200 derivative award units (reported A, $0.00 acquisition price).
• Sell-to-cover disposals: 7,223 shares at $11.66 (weighted avg; range $11.17–$11.91) and 14,038 shares at $11.76 (weighted avg; range $11.22–$12.095). Total shares sold = 21,261; total proceeds ≈ $249,241.
• Vesting/terms: Footnotes state the RSUs vest 25% each on March 1 of 2027–2030 (standard four-year schedule). A separate footnote describes an option-style vesting schedule (25% on 3/1/2027, remainder monthly to 3/1/2030) for the derivative award.
• The filing was submitted on 2026-03-03 covering transactions through 2026-03-01; no late‑filing flag is indicated in the filing.
• Shares owned after these transactions: not specified in the public Form 4 excerpt.

Context

• The sales were automatic “sell-to-cover” transactions to satisfy statutory tax withholding tied to the award — per the filing footnote, these were not discretionary open-market sales by the insider. Such sell-to-cover actions are common when RSUs vest and are generally not interpreted as a separate bearish signal.
• The awards are time‑based (multi-year vesting), so the insider will not immediately receive all shares; future vesting dates are March 1 of 2027–2030 (or monthly thereafter for the option-style award).
• For retail investors, granted RSUs indicate ongoing executive compensation alignment with shareholders, while the automatic sales simply fund required taxes rather than represent a market-driven sale.